Table 5 Less common adverse events during NACT (any grade ≥3 with pembrolizumab irrespective of relationship to treatment not shown in Table 4)
No. of patients with grade ≥3 adverse event (%) | NACT alone (n = 30) | NACT + pembrolizumab (n = 61) |
|---|---|---|
Pulmonary embolism | 1 (3) | 2 (3) |
Intestinal obstruction | 1 (3) | 1 (2) |
Pyelonephritis | 1 (3) | 1 (2) |
Sepsis | 1 (3) | 1 (2)a |
Brain empyema | 0 | 1 (2)a |
Perinephric abscess | 0 | 1 (2)b |
Peritonitis | 0 | 1 (2)b |
Staphylococcal sepsis | 0 | 1 (2)b |
Central bone marrow aplasia | 0 | 1 (2) |
Leukocytosis | 0 | 1 (2) |
Intra-abdominal fluid collection | 0 | 1 (2) |
C-reactive protein increased | 0 | 1 (2) |
Cachexia | 0 | 1 (2) |
Cerebral hemorrhage | 0 | 1 (2) |
Cerebral thromboembolic event | 0 | 1 (2) |
Cough | 0 | 1 (2) |
Venous thrombosis | 0 | 1 (2) |
Hemorrhagic shock | 0 | 1 (2) |
